Sign in Subscribe
Stem cells

Mesenchymal Stem Cells Show Promise in Treating Pulmonary Fibrosis

Strategic Insights

— 1 min read

A new study published in Frontiers in Microbiology suggests that human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) may be a promising therapeutic strategy for treating idiopathic pulmonary fibrosis (IPF), a chronic and progressive pulmonary disease. The study, conducted by researchers at the Second Affiliated Hospital of Fujian Medical University, found that HUC-MSCs alleviated IPF symptoms in mice by modulating dysregulated metabolic pathways and improving microbiota function.

Key Takeaways:

  • Researchers used a mouse model of IPF to study the effects of HUC-MSCs on lung morphology, gene expression, and inflammatory cytokine levels.
  • The study found that HUC-MSCs restored alveolar morphology and reduced the expression of a-SMA, FN1, and COL1A1, as well as the inflammatory cytokines TNF-a, IL-1b, IL-6, and TGF-b1.
  • The 16S rDNA sequencing results indicated that HUC-MSCs treatment decreased microbiota diversity and abundance, and the metabolomics analysis revealed notable differences in organic acids, lipids, phenylpropanoids, and organic nitrogen compounds.
  • The study suggests that HUC-MSCs may exert antifibrotic effects through metabolic pathways, and further exploration of these mechanisms is needed.
  • The study provides new insights into the potential mechanisms and treatments of IPF.

Statistics:

  • Thirty mice were used in the study, divided into three groups: Control, BLM, and BLM + HUC-MSCs.
  • The study found that HUC-MSCs treatment decreased the abundance-based coverage estimator (ACE) and Shannon indices, indicating a decrease in microbiota diversity.
  • The metabolomics analysis revealed significant differences in the levels of 21 candidate metabolites, including 12 organic acids and derivatives, 5 lipids and lipid-like molecules, 2 phenylpropanoids, and 2 polyketides.
  • The study suggests that HUC-MSCs may be a promising therapeutic strategy for treating IPF, but further research is needed to confirm the findings.

Sources:

  • "Preliminary exploration of the ability of HUC-MSCs to restore the lung microbiota and related metabolite disorders in IPF treatment: combining 16S sequencing and metabolite analysis". Frontiers in Microbiology, 2025;16:1645577.
  • Second Affiliated Hospital of Fujian Medical University. "Research Data from Second Affiliated Hospital of Fujian Medical University Update Understanding of Mesenchymal Stem Cells (Preliminary exploration of the ability of HUC-MSCs to restore the lung microbiota and related metabolite disorders in IPF ...)".
  • Frontiers in Microbiology. "Frontiers in Microbiology can be contacted at: Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland."

Read more